Dr. Markman on Potential Neuropathy Biomarkers

The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.

Sonrotoclax monotherapy produced durable responses in Chinese patients with relapsed/refractory mantle cell lymphoma.

lan M. Thompson Jr., MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

UCSF Health’s Adam Blaisdell, MD, PhD, has been selected as an IGNITE fellow by the Cancer Research Institute.

BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.

Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.

Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Disparities Progress Report and what oncologists can do to combat them.